Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Summer;11(2):195-212.
doi: 10.1111/j.1527-3458.2005.tb00270.x.

Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties

Juanita Dortch-Carnes  1 , David E Potter
Affiliations
Review

Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties

Juanita Dortch-Carnes et al. CNS Drug Rev. 2005 Summer.

Abstract

Bremazocine is a kappa-opioid receptor agonist with potent analgesic and diuretic activities. As an analgesic it is three- to four-times more potent than morphine, as determined in both hot plate and tail flick tests. Bremazocine and other benzomorphan analogs were synthesized in an effort to produce opiates with greater kappa-opioid receptor selectivity and with minimal morphine-like side effects. Unlike morphine bremazocine is devoid of physical and psychological dependence liability in animal models and produces little or no respiratory depression. While bremazocine does not produce the characteristic euphoria associated with morphine and its abuse, it has been shown to induce dysphoria, a property that limits its clinical usefulness. Similarly to morphine, repeated administration of bremazocine leads to tolerance to its analgesic effect. It has been demonstrated that the marked diuretic effect of bremazocine is mediated primarily by the central nervous system. Because of its psychotomimetic side effects (disturbance in the perception of space and time, abnormal visual experience, disturbance in body image perception, de-personalization, de-realization and loss of self control) bremazocine has limited potential as a clinical analgesic. However, its possible utility for the therapy of alcohol and drug addiction warrants further consideration because of its ability to decrease ethanol and cocaine self-administration in non-human primates. In addition, the ability of bremazocine-like drugs to lower intraocular pressure and to minimize ischemic damage in animal models suggests their possible use in the therapy of glaucoma and cardiovascular disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aitchison KA, Baxter GF, Awan MM, Smith M, Yellon DM, Opie LH. Opposing effects on infarction of δ‐and k‐opioid receptor activation in the isolated rat heart: Implications for ischemic preconditioning. Basic Res Cardiol 2000;95:1–10. - PubMed
    1. Amarante LH, Duarte ID. The k‐opioid agonist (+/−)‐bremazocine elicits peripheral antinociception by activation of the L‐arginine/nitric oxide/cyclic GMP pathway. Eur J Pharmacol 2002;454(1):19–23. - PubMed
    1. Archer S, Glick SD, Bidlack J. Cyclazocine revisited. Neurochem Res 1996;21:1369–1373. - PubMed
    1. Aziz LA, Forsling ML, Woolf CJ. The effect of intracerebroventricular injections of morphine on vasopressin release in the rat. J Physiol 1981;311:401–409. - PMC - PubMed
    1. Banna NR, Al‐Amen HA, Jabbur SJ. Selective inhibition of nociceptive flexion reflex discharge by the k agonist bremazocine. Neuropharmacology 1987;26(2/3):271–274. - PubMed

Publication types

MeSH terms